Sichuan Hebang Biotechnology (603077) Fundamentals 2026 — Revenue Analysis | SniperIQ
Sichuan Hebang Biotechnology (603077) is a CN-listed Basic Materials company in Chemicals with a market capitalization of ¥18.9B, trading at ¥2.36 on the SHH. This SniperIQ fundamentals page covers Sichuan Hebang Biotechnology's valuation, profitability (net margin -5.5%), revenue (¥7.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sichuan Hebang Biotechnology's market cap?
Sichuan Hebang Biotechnology (603077) has a market capitalization of approximately ¥18.9B, trading at ¥2.36 on the SHH. Market cap moves with the live share price.
What is Sichuan Hebang Biotechnology's P/E ratio?
Sichuan Hebang Biotechnology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Sichuan Hebang Biotechnology?
Sichuan Hebang Biotechnology runs a net profit margin of -5.5%, a gross margin of 13.6%, and an operating margin of -4.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sichuan Hebang Biotechnology generate?
Sichuan Hebang Biotechnology reported revenue of ¥7.2B for fiscal year 2025, with net income of -¥536M and earnings per share (EPS) of -0.0672. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sichuan Hebang Biotechnology pay a dividend?
Sichuan Hebang Biotechnology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sichuan Hebang Biotechnology financially healthy?
Sichuan Hebang Biotechnology carries a debt-to-equity ratio of 0.50x and a current ratio of 3.85x, with a market beta of 0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sichuan Hebang Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sichuan Hebang Biotechnology (603077) the key facts are: market cap ¥18.9B, revenue ¥7.2B, 52-week range 1.84-3.54. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Sichuan Hebang Biotechnology's full fundamentals live
Get Sichuan Hebang Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.